Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADVAX: SBRT + Ipilimumab in Metastatic Melanoma
NCT01970527Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Mar 2014
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by University of Washington. Primary endpoints: Immune-related Clinical Response, Immune-related Progression-free Survival at 6 months and 2 more. Started Mar 2014; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01970527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970527.